Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of meflunidone in preparation of medicine for treating acute kidney injury

A technology of acute kidney injury and meflunidone, applied in the field of application of meflunidone in the preparation of drugs for the treatment of acute kidney injury, to achieve the effect of creatinine level protection

Active Publication Date: 2021-10-01
CENT SOUTH UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For a long time, the clinical treatment of AKI has always followed the principle of symptomatic support, waiting for the outcome of the renal disease itself. So far, there is no one that can be used to reduce renal tissue damage or promote renal repair or prevent chronic renal fibrosis in the later stage of AKI. Therapeutic drugs approved for marketing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of meflunidone in preparation of medicine for treating acute kidney injury
  • Application of meflunidone in preparation of medicine for treating acute kidney injury
  • Application of meflunidone in preparation of medicine for treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0018] An application of meflunidone in the preparation of medicines for treating acute kidney injury.

[0019] In order to prove the effect of meflunidone in the preparation of drugs for the treatment of acute kidney injury, this example provides the following experiments to observe the curative effect of meflunidone in the treatment of ischemia-reperfusion-induced AKI in mice:

[0020] 1. Experimental method

[0021] The experimental animal model of ischemia-reperfusion-induced AKI was prepared to observe the curative effect of meflunidone on AKI.

[0022] Taking SPF grade C57BL / 6 mice (7-8 weeks old, male, body weight 20-22g) as the experimental subjects, they were divided into 7 groups, namely control group, model group, meflunidone 25mg / kg treatment group, Meflunidone 50mg / kg treatment group, meflunidone 75mg / kg treatment group, meflunidone 100mg / kg treatment group and meflunidone 125mg / kg treatment group. Two days before modeling (D1), meflunidone was given by intragas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of meflunidone in preparation of a medicine for treating acute kidney injury. When meflunidone is applied to ischemia reperfusion induced AKI mice for treatment, renal tubule pathological injuries can be relieved, the renal function can be improved, and the levels of renal function indexes of urea nitrogen and creatinine can be improved. It is shown that the meflunidone has a treatment effect on the AKI, that is, the medicine prepared from the meflunidone is suitable for treating the AKI. The administration dosage of the meflunidone to a human body is 12.8 mg / kg.

Description

technical field [0001] The present invention relates to ZHC-116, 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridine-2(1H )-ketone (abbreviated as meflunidone) new medical application. Background technique [0002] Acute kidney injury (AKI) is a common clinical syndrome, its occurrence is often accompanied by prolonged hospitalization, and some patients with poor prognosis will further develop into chronic kidney disease. About 13 million people worldwide suffer from AKI every year (85% of patients live in developing countries), and about 1.7 million people die from AKI and its complications. AKI can occur in many clinical disciplines, especially in the ICU with an incidence of more than 50%. In my country, a large-sample multi-center epidemiological survey data showed that according to the diagnostic criteria and extended criteria of KDIGO AKI, the incidence of AKI was 0.99% and 2.03%, while the in-hospital mortality rate was as high as 12.4%...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P13/12
CPCA61K31/496A61P13/12
Inventor 彭张哲陶立坚胡高云李乾斌孟婕
Owner CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com